Kaleido Biosciences Reports Second Quarter 2021 Financial Results
–On track to report topline data from a clinical study of KB295 in patients with mild-to-moderate ulcerative colitis by end of third quarter–
–Kaleido and the COPD Foundation to collaborate on the development of KB109 in patients with COPD; plan to initiate…
